The goal of this randomized clinical trial is to evaluate the Postoperative Pain and Flare-Up incidence following the use of Bio-Ceramic Based Intra-Canal Medication in Diabetic type II Patients compared to the Calcium Hydroxide based Intra-canal medicament.
The main questions it aims to answer are:
1. Is there any difference between using the two intracanal medicaments in the aspects of postoperative pain and flare-up incidence in diabetic type II patients? 2. Do intracanal medications reduce postoperative pain and flare-up incidence in diabetic type II patients?
Participants will be divided into two groups:
( both groups will receive root canal treatment in single rooted teeth) then: First group: will receive "Calcium Hydroxide based" intracanal medicament Second group: will receive "Bio-Ceramic Based" intracanal medicament
Postoperative pain will be assessed using:
* visual analog scale (VAS), A scale from (0 to 10) where "0" means no pain and "10" means a severe pain that has never faced before. * Patients will be contacted by phone at 6, 12, 24, 48, 72 hours and 7 days after the first visit to collect the postoperative pain data.
Flare-up is assessed:
\- by asking the patient to notify the investigator if any sudden severe pain or swelling takes place.
Patients with controlled diabetes mellitus type II.
with periapical lesion ranging (1-2mm) in diameter.
with complete root formation.
Without calcified root canals.
Pregnant females.
Patients with other systemic diseases in combination with diabetes mellitus.
Patients under antibiotic or analgesic administration.
Patients with facial swelling.
Parallel
Calcium Hydroxide Intracanal medication
DrugTreated using calcium hydroxide based material as an intracanal medicament
bioceramic based intracanal medication
Drugtreated using bio-ceramic based material as an intracanal medicament
postoperative pain intensity
Postoperative pain is to be assessed using visual analog scale (VAS), A scale from (0 to 10) where "0" means no pain and "10" means a severe pain that has never faced before. Patients will be contacted by phone at 6, 12, 24, 48, 72 hours and 7 days after the first visit to collect the postoperative pain data.
Flare-Up Incidence
Flare-up is assessed through asking the patient to notify the investigator if any sudden severe pain or swelling takes place. This could require an unscheduled emergency visit or prescription of additional medication.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
